James Convill1,2, Fiona Blackhall3,4, Janelle Yorke3,4, Corrine Faivre-Finn3,4, Fabio Gomes3. 1. The Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester, M20 4BX, UK. james.convill2@nhs.net. 2. Faculty of Biology, Medicine and Health, University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PG, UK. james.convill2@nhs.net. 3. The Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester, M20 4BX, UK. 4. Faculty of Biology, Medicine and Health, University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PG, UK.
Abstract
INTRODUCTION: Smoking cessation following lung cancer diagnosis is recommended to improve patient outcomes. Electronic Patient Reported Outcome Measures (ePROMs) may be useful for identifying and facilitating cessation support in patients that continue to smoke after a cancer diagnosis. The primary aim was to investigate the level of agreement between clinician-reported and self-reported patient smoking status during the first visit to a cancer centre (I). Secondary aims included investigating differences between cancer-specific characteristics between never smokers and current/ex-smokers (IIA), and the self-reported frequency of smoking cessation after diagnosis of lung cancer (IIB). METHODS: Retrospective single-centre study carried out at a tertiary cancer centre in the UK. Lung cancer patients that completed at least one ePROM questionnaire within 6 weeks of their first visit to the cancer centre (baseline), between February 2019 and February 2020, were included in the study. All ePROM questionnaires included a question regarding smoking status to allow comparison with the clinician records. Patients were offered these electronic questionnaires at each subsequent visit to the hospital. RESULTS: Of 195 patients included, 24 (12.3%) demonstrated discordance between clinician-reported and self-reported smoking status at the baseline assessment. Clinician-reported 'current smokers' were more likely to be discordant with self-reported smoking status, compared with clinician-reported 'ex-smokers' and 'never smokers' (P = 0.017). Never smokers were more likely to have adenocarcinoma (P < 0.005), present with stage IV cancer (P = 0.023) and receive treatment with palliative intention (P = 0.042), compared with current and ex-smokers. Of those that were reported by clinicians as being current smokers, 9/38 (23.7%) were self-reported ex-smokers. A sub-group of 137 patients completed at least one additional ePROM questionnaire after the baseline and were included in the smoking cessation analysis. Thirty-eight patients were clinician-reported as 'current smokers' at baseline. Of these, 9 subsequently stopped smoking, 17 continued and 3 had short periods of cessation, identified through self-reporting. CONCLUSION: In most cases, there is concordance between clinician- and self-reported smoking status. A small area of discordance was identified where clinicians reported some patients as 'current smokers', whilst patients self-reported having stopped. The causes for this were not explored and require further investigation. This study supports the use of ePROMs as a helpful tool to assess smoking status, and it can be used to identify patients for smoking cessation referral.
INTRODUCTION: Smoking cessation following lung cancer diagnosis is recommended to improve patient outcomes. Electronic Patient Reported Outcome Measures (ePROMs) may be useful for identifying and facilitating cessation support in patients that continue to smoke after a cancer diagnosis. The primary aim was to investigate the level of agreement between clinician-reported and self-reported patient smoking status during the first visit to a cancer centre (I). Secondary aims included investigating differences between cancer-specific characteristics between never smokers and current/ex-smokers (IIA), and the self-reported frequency of smoking cessation after diagnosis of lung cancer (IIB). METHODS: Retrospective single-centre study carried out at a tertiary cancer centre in the UK. Lung cancer patients that completed at least one ePROM questionnaire within 6 weeks of their first visit to the cancer centre (baseline), between February 2019 and February 2020, were included in the study. All ePROM questionnaires included a question regarding smoking status to allow comparison with the clinician records. Patients were offered these electronic questionnaires at each subsequent visit to the hospital. RESULTS: Of 195 patients included, 24 (12.3%) demonstrated discordance between clinician-reported and self-reported smoking status at the baseline assessment. Clinician-reported 'current smokers' were more likely to be discordant with self-reported smoking status, compared with clinician-reported 'ex-smokers' and 'never smokers' (P = 0.017). Never smokers were more likely to have adenocarcinoma (P < 0.005), present with stage IV cancer (P = 0.023) and receive treatment with palliative intention (P = 0.042), compared with current and ex-smokers. Of those that were reported by clinicians as being current smokers, 9/38 (23.7%) were self-reported ex-smokers. A sub-group of 137 patients completed at least one additional ePROM questionnaire after the baseline and were included in the smoking cessation analysis. Thirty-eight patients were clinician-reported as 'current smokers' at baseline. Of these, 9 subsequently stopped smoking, 17 continued and 3 had short periods of cessation, identified through self-reporting. CONCLUSION: In most cases, there is concordance between clinician- and self-reported smoking status. A small area of discordance was identified where clinicians reported some patients as 'current smokers', whilst patients self-reported having stopped. The causes for this were not explored and require further investigation. This study supports the use of ePROMs as a helpful tool to assess smoking status, and it can be used to identify patients for smoking cessation referral.
Authors: Yolanda I Garces; Ping Yang; Julia Parkinson; Xinghua Zhao; Jason A Wampfler; Jon O Ebbert; Jeff A Sloan Journal: Chest Date: 2004-12 Impact factor: 9.410
Authors: Jun Chen; Yingwei Qi; Jason A Wampfler; Aminah Jatoi; Yolanda I Garces; Allan J Busta; Sumithra J Mandrekar; Ping Yang Journal: Eur J Cancer Date: 2012-01-12 Impact factor: 9.162
Authors: Michael J Thun; S Jane Henley; David Burns; Ahmedin Jemal; Thomas G Shanks; Eugenia E Calle Journal: J Natl Cancer Inst Date: 2006-05-17 Impact factor: 13.506
Authors: Sevin Baser; Vickie R Shannon; Georgie A Eapen; Carlos A Jimenez; Amir Onn; E Lin; Rodolfo C Morice Journal: Chest Date: 2006-12 Impact factor: 9.410
Authors: Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag Journal: J Natl Cancer Inst Date: 2009-11-17 Impact factor: 13.506
Authors: Nelson A Morales; Michelle A Romano; K Michael Cummings; James R Marshall; Andrew J Hyland; Alan Hutson; Graham W Warren Journal: Cancer Causes Control Date: 2013-04-04 Impact factor: 2.506